ClinicalTrials.gov: newly registered trials· Johns Hopkins University·· 15 days agoAI score40
Psilocybin for Amblyopia - Targeting Critical Periods in Humans (PATCH)
AI summary
A newly registered trial, PATCH, will evaluate whether psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. The study will assess whether ingesting psilocybin, a naturally occurring psychoactive compound, can enhance treatment outcomes in this population.
Key facts
- Kind of item
- Trial registrations
- Compound
- Psilocybin
- Jurisdiction
- United States
- Trial registration
- NCT07920081 (ClinicalTrials.gov)
- Source
- ClinicalTrials.gov: newly registered trials (clinicaltrials.gov)
- Published
- Original
- Read it at clinicaltrials.gov
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: ClinicalTrials.gov: newly registered trials · clinicaltrials.gov
Connected to
- Kind of item
- Trial registrations
- Compound
- Psilocybin
- Jurisdiction
- United States